Dobutamine increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation

Frederick (Fred) Tibayan, Asha N. Chesnutt, Hans G. Folkesson, Jon Eandi, Michael A. Matthay

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Although it is well known that beta-adrenergic agonist stimulation increases alveolar epithelial sodium and fluid transport, it is not known whether the beta-1 or the beta-2 receptor mediates this effect. Two clinically relevant beta-adrenergic agonists, dopamine (beta-1 agonist) and dobutamine (beta-1 and beta-2 agonist) were used to define the contribution of these two beta-receptors to beta-adrenergic stimulated fluid clearance from the air spaces of the lungs. Alveolar fluid clearance was measured in anesthetized, ventilated rats over one hour after instilling an isosmolar 5% albumin solution in Ringer's lactate with 3 μCi 125I-albumin. The concentrations of the labeled and unlabeled albumin were used to quantify alveolar liquid clearance. Dopamine, whether given intra-alveolar (10-4 M) or intravenously (5-10 μg/kg/min), had no effect. However, both intra- alveolar (10-4 M) and intravenous (5 μg/kg/min) dobutamine increased alveolar liquid clearance by approximately 50% over one hour compared to controls. ICI 118,551, a potent and specific beta-2 antagonist, blocked the effect of dobutamine. The dobutamine effect was blocked by amiloride (10-3 M), an inhibitor of sodium uptake. In summary, the beta-2 receptor mediates beta-adrenergic stimulation of alveolar epithelial sodium and fluid transport.

Original languageEnglish (US)
Pages (from-to)438-444
Number of pages7
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume156
Issue number2 I
StatePublished - 1997
Externally publishedYes

Fingerprint

Dobutamine
Albumins
Adrenergic beta-Agonists
Sodium
Dopamine
Adrenergic beta-2 Receptors
Amiloride
Receptors, Adrenergic, beta
Air
Lung

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Dobutamine increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation. / Tibayan, Frederick (Fred); Chesnutt, Asha N.; Folkesson, Hans G.; Eandi, Jon; Matthay, Michael A.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 156, No. 2 I, 1997, p. 438-444.

Research output: Contribution to journalArticle

Tibayan, Frederick (Fred) ; Chesnutt, Asha N. ; Folkesson, Hans G. ; Eandi, Jon ; Matthay, Michael A. / Dobutamine increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation. In: American Journal of Respiratory and Critical Care Medicine. 1997 ; Vol. 156, No. 2 I. pp. 438-444.
@article{fc9607fd18c44dc2abace081da6ec4d3,
title = "Dobutamine increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation",
abstract = "Although it is well known that beta-adrenergic agonist stimulation increases alveolar epithelial sodium and fluid transport, it is not known whether the beta-1 or the beta-2 receptor mediates this effect. Two clinically relevant beta-adrenergic agonists, dopamine (beta-1 agonist) and dobutamine (beta-1 and beta-2 agonist) were used to define the contribution of these two beta-receptors to beta-adrenergic stimulated fluid clearance from the air spaces of the lungs. Alveolar fluid clearance was measured in anesthetized, ventilated rats over one hour after instilling an isosmolar 5{\%} albumin solution in Ringer's lactate with 3 μCi 125I-albumin. The concentrations of the labeled and unlabeled albumin were used to quantify alveolar liquid clearance. Dopamine, whether given intra-alveolar (10-4 M) or intravenously (5-10 μg/kg/min), had no effect. However, both intra- alveolar (10-4 M) and intravenous (5 μg/kg/min) dobutamine increased alveolar liquid clearance by approximately 50{\%} over one hour compared to controls. ICI 118,551, a potent and specific beta-2 antagonist, blocked the effect of dobutamine. The dobutamine effect was blocked by amiloride (10-3 M), an inhibitor of sodium uptake. In summary, the beta-2 receptor mediates beta-adrenergic stimulation of alveolar epithelial sodium and fluid transport.",
author = "Tibayan, {Frederick (Fred)} and Chesnutt, {Asha N.} and Folkesson, {Hans G.} and Jon Eandi and Matthay, {Michael A.}",
year = "1997",
language = "English (US)",
volume = "156",
pages = "438--444",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "2 I",

}

TY - JOUR

T1 - Dobutamine increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation

AU - Tibayan, Frederick (Fred)

AU - Chesnutt, Asha N.

AU - Folkesson, Hans G.

AU - Eandi, Jon

AU - Matthay, Michael A.

PY - 1997

Y1 - 1997

N2 - Although it is well known that beta-adrenergic agonist stimulation increases alveolar epithelial sodium and fluid transport, it is not known whether the beta-1 or the beta-2 receptor mediates this effect. Two clinically relevant beta-adrenergic agonists, dopamine (beta-1 agonist) and dobutamine (beta-1 and beta-2 agonist) were used to define the contribution of these two beta-receptors to beta-adrenergic stimulated fluid clearance from the air spaces of the lungs. Alveolar fluid clearance was measured in anesthetized, ventilated rats over one hour after instilling an isosmolar 5% albumin solution in Ringer's lactate with 3 μCi 125I-albumin. The concentrations of the labeled and unlabeled albumin were used to quantify alveolar liquid clearance. Dopamine, whether given intra-alveolar (10-4 M) or intravenously (5-10 μg/kg/min), had no effect. However, both intra- alveolar (10-4 M) and intravenous (5 μg/kg/min) dobutamine increased alveolar liquid clearance by approximately 50% over one hour compared to controls. ICI 118,551, a potent and specific beta-2 antagonist, blocked the effect of dobutamine. The dobutamine effect was blocked by amiloride (10-3 M), an inhibitor of sodium uptake. In summary, the beta-2 receptor mediates beta-adrenergic stimulation of alveolar epithelial sodium and fluid transport.

AB - Although it is well known that beta-adrenergic agonist stimulation increases alveolar epithelial sodium and fluid transport, it is not known whether the beta-1 or the beta-2 receptor mediates this effect. Two clinically relevant beta-adrenergic agonists, dopamine (beta-1 agonist) and dobutamine (beta-1 and beta-2 agonist) were used to define the contribution of these two beta-receptors to beta-adrenergic stimulated fluid clearance from the air spaces of the lungs. Alveolar fluid clearance was measured in anesthetized, ventilated rats over one hour after instilling an isosmolar 5% albumin solution in Ringer's lactate with 3 μCi 125I-albumin. The concentrations of the labeled and unlabeled albumin were used to quantify alveolar liquid clearance. Dopamine, whether given intra-alveolar (10-4 M) or intravenously (5-10 μg/kg/min), had no effect. However, both intra- alveolar (10-4 M) and intravenous (5 μg/kg/min) dobutamine increased alveolar liquid clearance by approximately 50% over one hour compared to controls. ICI 118,551, a potent and specific beta-2 antagonist, blocked the effect of dobutamine. The dobutamine effect was blocked by amiloride (10-3 M), an inhibitor of sodium uptake. In summary, the beta-2 receptor mediates beta-adrenergic stimulation of alveolar epithelial sodium and fluid transport.

UR - http://www.scopus.com/inward/record.url?scp=0030753759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030753759&partnerID=8YFLogxK

M3 - Article

VL - 156

SP - 438

EP - 444

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 2 I

ER -